| Ipca Laboratories Ltd | Industry : (Pharmaceuticals) | |
|---|---|---|
|
BSE Code : 524494 |
NSE Symbol : IPCALAB |
P/E(TTM) : 64.16 |
|
ISIN Demat : INE571A01038 |
Div & Yield% : 0.26 |
EPS(TTM) : 24.27 |
|
Book Value(₹) : 250.24 |
Market Cap(₹Cr) : 39,505.55 |
Face Value(₹) : 1.00 |
| Particulars | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 |
|---|---|---|---|---|---|
| INCOME : | |||||
| Sales Turnover | 6,166.46 | 5,814.62 | 5,438.30 | 5,139.16 | 4,367.43 |
| Excise Duty | - | - | - | - | 29.61 |
| Net Sales | 6,166.46 | 5,814.62 | 5,438.30 | 5,139.16 | 4,337.82 |
| Other Income | 111.29 | 111.19 | 52.92 | 62.24 | 64.69 |
| Stock Adjustments | 55.19 | -104.09 | 126.00 | 170.73 | 155.05 |
| Total Income | 6,332.94 | 5,821.72 | 5,617.22 | 5,372.13 | 4,557.56 |
| EXPENDITURE : | |||||
| Raw Materials | 2,033.57 | 1,964.94 | 1,911.88 | 1,753.21 | 1,635.75 |
| Power and Fuel Cost | 253.33 | 277.21 | 237.44 | 201.48 | 196.82 |
| Other Manufacturing Expenses | 356.81 | 311.74 | 279.03 | 225.25 | 198.30 |
| Selling and Administration Expenses | 846.95 | 812.67 | 612.89 | 551.23 | 523.99 |
| Miscellaneous Expenses | 314.87 | 236.31 | 179.67 | 113.31 | 149.41 |
| Employee Benefit Expenses | 1,336.19 | 1,193.39 | 1,102.14 | 948.84 | 870.79 |
| Less: Preoperative Expenditure | - | - | - | - | - |
| Total Expenses | - | - | - | - | - |
| Operating Profit | 1,191.22 | 1,025.46 | 1,294.17 | 1,578.81 | 982.50 |
| Interest | 122.58 | 46.34 | 10.41 | 11.13 | 18.84 |
| Gross Profit | 1,068.64 | 979.12 | 1,283.76 | 1,567.68 | 963.66 |
| Depreciation | 246.48 | 228.63 | 209.65 | 187.72 | 178.69 |
| Profit Before Tax | 822.16 | 750.49 | 1,074.11 | 1,379.96 | 784.97 |
| Current Tax | 288.01 | 223.95 | 197.28 | 244.98 | 137.98 |
| Fringe Benefit tax | - | - | - | - | - |
| Deferred Tax | 3.74 | 20.84 | 16.46 | -5.79 | -5.47 |
| Reported Net Profit | 530.41 | 505.70 | 860.37 | 1,140.77 | 652.46 |
| Extraordinary Items | -69.52 | 17.51 | 7.86 | 8.34 | 10.86 |
| Adjusted Net Profit | 599.93 | 488.19 | 852.51 | 1,132.43 | 641.60 |
| Adjustment below Net Profit | -1.39 | -2.05 | 1.15 | -0.16 | -107.04 |
| Profit/Loss Balance carried down | 4,478.52 | 4,076.35 | 3,316.31 | 2,277.18 | 1,752.53 |
| Statutory Appropriations | - | - | - | - | - |
| Appropriations | 50.74 | 101.48 | 101.48 | 101.48 | 20.77 |
| P & L Balance carried down | 4,956.80 | 4,478.52 | 4,076.35 | 3,316.31 | 2,277.18 |
| Dividend | - | - | - | - | - |
| Preference Dividend | - | - | - | - | - |
| Equity Dividend (%) | 400.00 | 400.00 | 400.00 | 400.00 | 250.00 |
| Dividend Per Share(Rs) | 4.00 | 4.00 | 4.00 | 8.00 | 5.00 |
| Earnings Per Share-Unit Curr | 20.91 | 19.93 | 33.91 | 89.93 | 51.64 |
| Earnings Per Share(Adj)-Unit Curr | 20.91 | 19.93 | 33.91 | 44.97 | 25.82 |
| Book Value | 250.24 | 231.66 | 215.84 | 374.67 | 290.11 |
| Book Value(Adj)-Unit Curr | 250.24 | 231.66 | 215.84 | 187.34 | 145.06 |